Klaas Poelstra
Corporate Officer/Principal chez University of Groningen
Postes actifs de Klaas Poelstra
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| University of Groningen | Corporate Officer/Principal | 21/08/2009 | - |
Historique de carrière de Klaas Poelstra
Anciens postes connus de Klaas Poelstra
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
BiOrion Technologies BV
 BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Directeur Technique/Scientifique/R&D | 01/01/2003 | - |
| Fondateur | 21/08/2009 | - |
Statistiques
Internationale
| Pays-Bas | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
BiOrion Technologies BV
BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Bourse
- Insiders
- Klaas Poelstra
- Expérience
